Roivant Sciences Ltd (ROIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 1,571 | 2,170 | 7,570 | 9,018 | 4,475 |
| Cost of Goods | 111 | 154 | 205 | 259 | 234 |
| Gross Profit | 1,460 | 2,016 | 7,365 | 8,759 | 4,241 |
| Operating Expenses | 307,804 | 287,092 | 292,535 | 283,399 | 346,188 |
| Operating Income | -306,233 | -284,922 | -284,965 | -274,381 | -341,713 |
| Other Income | 147,189 | 15,660 | 81,911 | 39,868 | 117,330 |
| Pre-tax Income | -159,044 | -269,262 | -203,054 | -234,513 | -224,383 |
| Income Tax | 6,995 | 4,649 | 49,321 | -25,568 | 12,458 |
| Net Income Continuous | -166,039 | -273,911 | -252,375 | -208,945 | -236,841 |
| Net Income Discontinuous | N/A | N/A | 0 | 327,020 | -43,083 |
| Minority Interests | -52,520 | -50,556 | -45,900 | -51,306 | -49,740 |
| Net Income | $-113,519 | $-223,355 | $-206,475 | $169,381 | $-230,184 |
| EPS Basic Total Ops | -0.17 | -0.33 | -0.29 | 0.23 | -0.31 |
| EPS Basic Continuous Ops | -0.24 | -0.40 | -0.35 | -0.29 | -0.32 |
| EPS Basic Discontinuous Ops | N/A | N/A | 0.00 | 0.45 | -0.06 |
| EPS Diluted Total Ops | -0.17 | -0.33 | -0.28 | 0.23 | -0.31 |
| EPS Diluted Continuous Ops | -0.24 | -0.40 | -0.35 | -0.29 | -0.32 |
| EPS Diluted Discontinuous Ops | N/A | N/A | 0.01 | 0.45 | -0.06 |
| EPS Diluted Before Non-Recurring Items | -0.40 | -0.30 | -0.31 | -0.20 | -0.37 |
| EBITDA(a) | $-305,312 | $-283,824 | $-283,540 | $-271,460 | $-336,871 |